Based on the data above, this study proposed to compare the efficacy and safety of the two regimens (weekly docetaxel plus cisplatin followed by gemcitabine vs. gemcitabine plus cisplatin followed by weekly docetaxel) in metastatic of locally advanced non-small cell lung cancer.